Publication:
Machine Learning Improves Cardiovascular Risk Definition for Young, Asymptomatic Individuals

dc.contributor.authorSanchez-Cabo, Fatima
dc.contributor.authorRossello, Xavier
dc.contributor.authorFuster, Valentin
dc.contributor.authorde Benito, Fernando M
dc.contributor.authorManzano, Jose Pedro
dc.contributor.authorSilla-Castro, Juan Carlos
dc.contributor.authorFernandez-Alvira, Juan Miguel
dc.contributor.authorOliva, Belen
dc.contributor.authorFernandez-Friera, Leticia
dc.contributor.authorLopez-Melgar, Beatriz
dc.contributor.authorMendiguren, Jose M
dc.contributor.authorSanz, Javier
dc.contributor.authorOrdovas, Jose M
dc.contributor.authorAndres, Vicente
dc.contributor.authorFernandez-Ortiz, Antonio
dc.contributor.authorBueno, Hector
dc.contributor.authorIbáñez, Borja
dc.contributor.authorGarcia-Ruiz, Jose M
dc.contributor.authorLara-Pezzi, Enrique
dc.contributor.funderCentro Nacional de Investigaciones Cardiovasculares Carlos III (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)
dc.contributor.funderFundación ProCNIC
dc.contributor.funderBanco Santander
dc.contributor.funderFundación AstraZeneca
dc.contributor.funderBristol-Myers Squibb
dc.contributor.funderNovartis
dc.date.accessioned2020-10-28T09:54:51Z
dc.date.available2020-10-28T09:54:51Z
dc.date.issued2020-10-06
dc.description.abstractBACKGROUND: Clinical practice guidelines recommend assessment of subclinical atherosclerosis using imaging techniques in individuals with intermediate atherosclerotic cardiovascular risk according to standard risk prediction tools. OBJECTIVES: The purpose of this study was to develop a machine-learning model based on routine, quantitative, and easily measured variables to predict the presence and extent of subclinical atherosclerosis (SA) in young, asymptomatic individuals. The risk of having SA estimated by this model could be used to refine risk estimation and optimize the use of imaging for risk assessment. METHODS: The Elastic Net (EN) model was built to predict SA extent, defined by a combined metric of the coronary artery calcification score and 2-dimensional vascular ultrasound. The performance of the model for the prediction of SA extension and progression was compared with traditional risk scores of cardiovascular disease (CVD). An external independent cohort was used for validation. RESULTS: EN-PESA (Progression of Early Subclinical Atherosclerosis) yielded a c-statistic of 0.88 for the prediction of generalized subclinical atherosclerosis. Moreover, EN-PESA was found to be a predictor of 3-year progression independent of the baseline extension of SA. EN-PESA assigned an intermediate to high cardiovascular risk to 40.1% (n = 1,411) of the PESA individuals, a significantly larger number than atherosclerotic CVD (n = 267) and SCORE (Systematic Coronary Risk Evaluation) (n = 507) risk scores. In total, 86.8% of the individuals with an increased risk based on EN-PESA presented signs of SA at baseline or a significant progression of SA over 3 years. CONCLUSIONS: The EN-PESA model uses age, systolic blood pressure, and 10 commonly used blood/urine tests and dietary intake values to identify young, asymptomatic individuals with an increased risk of CVD based on their extension and progression of SA. These individuals are likely to benefit from imaging tests or pharmacological treatment.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe PESA study is cofunded equally by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, and Banco Santander, Madrid, Spain. The study also receives funding from the Instituto de Salud Carlos III (PI15/02019) and the European Regional Development Fund “Una manera de hacer Europa.” The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). Dr. Bueno has received research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 and PI17/01799), AstraZeneca, Bristol-Myers Squibb and Novartis; has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb-Pfizer, and Novartis; and has received speaker fees or support for attending scientific meetings from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb-Pfizer, Novartis, and MEDSCAPE-the heart.org.es_ES
dc.format.number14es_ES
dc.format.page1674-1685es_ES
dc.format.volume76es_ES
dc.identifier.citationJ Am Coll Cardiol. 2020; 76(14):1674-1685es_ES
dc.identifier.doi10.1016/j.jacc.2020.08.017es_ES
dc.identifier.issn0735-1097
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17234
dc.identifier.pubmedID33004133es_ES
dc.identifier.puiL2007891822
dc.identifier.scopus2-s2.0-85091231710
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11236
dc.identifier.wos579523600008
dc.language.isoenges_ES
dc.publisherElsevier
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SEV-2015-0505es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI15/02019es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE16/00021es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/01799es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jacc.2020.08.017es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionaleses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Investigación Cardiovascular Traslacional Multidisciplinariaes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Bioinformáticaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Regulación Molecular de la Insuficiencia Cardiacaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Fisiopatología Cardiovascular Molecular y Genéticaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectASCVD
dc.subjectAtherosclerosis
dc.subjectCardiovascular risk scores
dc.subjectMachine-learning
dc.subjectSubclinical
dc.subject.decsEnfermedades Asintomáticas
dc.subject.decsFactores de Riesgo
dc.subject.decsHumanos
dc.subject.decsPersona de Mediana Edad
dc.subject.decsEstudios Prospectivos
dc.subject.decsFemenino
dc.subject.decsEnfermedades Cardiovasculares
dc.subject.decsAdulto
dc.subject.decsAprendizaje Automático
dc.subject.decsMasculino
dc.subject.meshCardiovascular Diseases
dc.subject.meshMale
dc.subject.meshProspective Studies
dc.subject.meshAdult
dc.subject.meshFemale
dc.subject.meshRisk Factors
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshAsymptomatic Diseases
dc.subject.meshMachine Learning
dc.titleMachine Learning Improves Cardiovascular Risk Definition for Young, Asymptomatic Individualses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationecd7f1e7-2399-4c06-bbc6-d1a2e86c0fbe
relation.isAuthorOfPublicationbbc835c4-284a-4845-8a6e-adf765b43cc1
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublication40cf6362-44fb-48e0-b487-d284eba597d2
relation.isAuthorOfPublication9fcf962d-359b-469d-a8ae-9b587ae4618c
relation.isAuthorOfPublication0aa264de-120d-4f7f-bb1d-c7bb913a04d8
relation.isAuthorOfPublication2cac2b58-fa25-494c-92c5-5ac91f3d2036
relation.isAuthorOfPublication4b2a0672-e9a0-4788-b256-d3170c84aab2
relation.isAuthorOfPublicatione0026bba-db67-4a42-8fa8-79005fe4857e
relation.isAuthorOfPublication465de6aa-7383-4ba5-b278-765f894f2c87
relation.isAuthorOfPublication56fd55f2-e9f6-4122-a4e0-f6494d4ff558
relation.isAuthorOfPublication3bb85851-071a-490a-976b-c234983847a7
relation.isAuthorOfPublicationc247543c-ab71-441c-8eec-b54f56c6a1ff
relation.isAuthorOfPublication4e417023-fc1f-41d2-8130-485f76466465
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublicationf8bdc86d-5800-41d9-865a-bf567a8acf9f
relation.isAuthorOfPublicatione7d4df9b-2306-4955-ba22-17d066e07612
relation.isAuthorOfPublication.latestForDiscoveryecd7f1e7-2399-4c06-bbc6-d1a2e86c0fbe
relation.isFunderOfPublication13936dca-3040-4689-8cca-a0d0960a0c50
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication1aef4c3b-1ee5-4534-83b4-3f3811c67280
relation.isFunderOfPublicationef935eeb-4c46-446a-868e-66e905683e75
relation.isFunderOfPublication2302598f-47dd-49b5-a26e-ae31bf61786e
relation.isFunderOfPublicationc096b94d-e5c0-47e7-9f20-3837d19a3e6b
relation.isFunderOfPublication02a578e8-d080-40ac-96cb-6deb6cf1ebd0
relation.isFunderOfPublication72800632-4d0e-454d-9663-024ab913e173
relation.isFunderOfPublication.latestForDiscovery13936dca-3040-4689-8cca-a0d0960a0c50
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
MachineLearningImprovesCardiovascular_2020.pdf
Size:
649.71 KB
Format:
Adobe Portable Document Format
Description:
Artículo